title: [Current status of treatment of refractory ascites in patients with liver cirrhosis].
abstract: Ascites is a common clinical manifestation of cirrhotic portal hypertension, and about 60%-80% of cirrhotic patients develop the symptom of ascites within 10 years. Once ascites occurs, the 5-year survival rate is reduced from 80% to 50%. With the progression of liver diseases, approximately 5%-10% of patients with ascites develop refractory ascites, and the median survival time is only 6-12 months. This article reviews the definition and diagnosis of refractory ascites, evaluation of prognostic factors, and treatment regimens, including large-volume paracentesis combined with protein supplementation, transjugular intrahepatic portosystemic shunt, and liver transplantation.
authors.affiliation: Department of Liver Disease and Digestive Interventional Radiology, Xijing Hospital of the Fourth Military Medical University, Xi'an 710032, China.
authors.forename: J
authors.initials: J
authors.lastname: Shao
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: G H
authors.initials: GH
authors.lastname: Han
authors.forename: D M
authors.initials: DM
authors.lastname: Fan
mesh_terms: D001201:Ascites / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications*; D016031:Liver Transplantation; D019152:Paracentesis / Q000379:methods; D019168:Portasystemic Shunt, Transjugular Intrahepatic; D016019:Survival Analysis; D015996:Survival Rate; D013995:Time